research Editorial: Targeted immunological therapies in dermatology
Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.
Search
for
Sort by
Research
960-990 / 1000+ results research Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib
Selumetinib causes fewer and less severe skin issues in children than binimetinib.
research 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
research Epidermal growth factor receptor/mitogen-activated kinase inhibitor treatment induces a distinct inflammatory hair follicle response that includes collapse of immune privilege
EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.
research Endocrine effects of long-term calcineurin inhibitor use in solid organ transplant recipients
Long-term use of calcineurin inhibitors in transplant patients can cause hormone issues that can be managed with proper care.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research Biochemical properties of red tilapia (Oreochromis niloticus) protein hydrolysates.
Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.
research A rare manifestation of STING-associated vasculopathy with onset in infancy: a case report
Early genetic testing and JAK inhibitors can help treat systemic inflammation in SAVI patients.
research Case Report: Baricitinib improved alopecia areata in a pediatric patient with atopic dermatitis
Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
research 097 LFA-1 blockade prevents the onset of alopecia areata in C3H/HeJ mice
Blocking LFA-1 prevents hair loss in mice.
research Computational Evaluation of Dibenzo Compounds as Potential Dual Inhibitors of Androgen Receptor and 5α-Reductase
Some dibenzo compounds might help treat cancer with fewer side effects.
research This Month in JAAD: October 2021
Oral baricitinib is effective and safe for treating alopecia areata.
research Systemic Therapies for Pediatric Alopecia Areata.
Janus kinase inhibitors are the most supported treatment for pediatric alopecia areata, while other options have limited evidence.
research Pattern hair loss distribution: a novel presentation for alopecia areata
Tofacitinib helped regrow hair in a teen with a unique pattern of alopecia areata.
research Immunomodulators in the treatment of cutaneous lymphoma
Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.
research Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
Cancer treatments often cause skin, nail, and hair problems.
research 26 Characterization of a murine model of aa induced by adoptive transfer of cultured lymph node cells
The study developed a mouse model for Alopecia Areata that responds to treatment, useful for future research.
research Oral tofacitinib for the treatment of alopecia areata in pediatric patients
Tofacitinib taken by mouth helps treat hair loss in children.
research Exploring the Use of Topical Tofacitinib in Pediatric Alopecia Totalis
Topical tofacitinib may help regrow hair in children with alopecia totalis.
research 0054 Treg-targeted therapies restrain disease in a murine model of alopecia areata
Enhancing Tregs can protect against alopecia areata.
research Clinical Case of Tofacitinib Therapy in Autoimmune Alopecia in Patient with Ulcerative Colitis
Tofacitinib can help hair grow back in alopecia patients but hair loss might return if the dose is lowered.
research 645 MIG6 is MEK-regulated and affects EGF-induced migration in mutant NRAS melanoma
Decreasing MIG6 can increase the movement and invasiveness of MEK-inhibited mutant NRAS melanoma, particularly when stimulated by EGF.
research Refractory alopecia universalis associated with dermatomyositis successfully treated with tofacitinib
A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
research Influence of interleukin‐1α on androgen receptor expression and cytokine secretion by cultured human dermal papilla cells
Interleukin‐1 α reduces androgen receptor levels and increases certain cytokines in human scalp cells.
research 056 IKZF1 and IKAROS overexpression contributes to the pathogenesis of alopecia areata
Too much IKZF1 and Ikaros protein may cause alopecia areata.
research Aberrant Activation of the Hedgehog Pathway in Cutaneous Melanoma: Therapeutic Potential of Pharmacological Inhibitors
Hedgehog pathway inhibitors could be effective in treating melanoma.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research The Functional Relevance of the Type 1 Cytokines IFN-γ and IL-2 in Alopecia Areata of C3H/HeJ Mice
IFN-γ and IL-2 are important for T cell activation in hair loss in mice.
research Modulating immune responses in alopecia: therapeutic insights and potential targets of antisense oligonucleotides
Targeting SIRT1 with antisense oligonucleotides could be a promising treatment for hair loss.